brentuximab vedotin (SGN-35)

DRUG2 trials

Sponsors

Memorial Sloan Kettering Cancer Center

Conditions

Hodgkin LymphomaHodgkin's Lymphoma

Phase 2

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

CompletedNCT01508312

Memorial Sloan Kettering Cancer CenterHodgkin's Lymphoma

Start: 2012-01-05End: 2024-03-14Updated: 2025-10-21

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

CompletedNCT01508312

Memorial Sloan Kettering Cancer CenterHodgkin's Lymphoma

Start: 2012-01-05End: 2024-03-14Updated: 2025-10-21

Unknown Phase

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Active, not recruitingNCT01868451

Memorial Sloan Kettering Cancer CenterHodgkin Lymphoma

Start: 2013-05-31End: 2026-05-31Updated: 2025-07-09

Related Papers

Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma

Blood Advances2023-09-1816 citations

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Blood2016-07-2576 citations

Metabolic tumor volume to predict event free survival in patients with relapsed/refractory HL treated with brentuximab vedotin-based salvage therapy.

Journal of Clinical Oncology2016-05-201 citations

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

2015-02-13186 citations